Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Endometrial Cancer Diagnostics Market: By Condition, By Test, By End-user and Geography
Endometrial Cancer Diagnostics Market size was valued at US$ 22.4 billion in 2023 and estimated to reach at US$ 29.4 billion by 2030, growing at a significant CAGR of 5.4% From 2024-2030. Endometrial Cancer is the most common form of uterine cancer as the endometrium is part of the uterus. Endometrial cancer is often called uterine cancer. It is the most commonly diagnosed gynecologic cancer. Endometrial cancer forms when cells in the inner lining of the uterus (endometrium) begin to grow out of control. Unlike breast and prostate cancer where screening tests are available to the general population endometrial cancer is most commonly diagnosed at endometrial biopsy in symptomatic patients. No generally applicable screening test is available. Among all test types hysteroscopy is most commonly recommended uterine cancer diagnostic test.
According to the American Cancer Society, in 2017, about 61380 new cases of uterine cancer were diagnosed and around 10,000 were dead. According to WHO, developed regions such as North America and Europe registers greater incidence rate for endometrial cancer due to lifestyle changes adopted by women. Women with abnormal vaginal bleeding are detected with endometrial cancer at an early stage. Endometrial cancer is the sixth most common cancer in women worldwide, according to statistics. Because of the increased prevalence of Endometrial Cancer Diagnostics Market is predicted to grow significantly. Other key factors contributing to the market's growth include rising female obesity, increased menopausal hormone therapy, changes in sedentary lifestyle, socioeconomic factors, rising consumption of unhealthy diet, rising occurrence of Polycystic Ovarian Syndrome (PCOS), and rising prevalence of breast or ovarian tumour. Another condition that contributes to the development of endometrial cancer is diabetes. Endometrial cancer is four times more likely in diabetes women than in non-diabetic women, according to the American Cancer Society. Endometrial cancer is caused by such factors in women.
Study Period
2024-2030Base Year
2023CAGR
5.4%Largest Market
North-AmericaFastest Growing Market
Asia Pacific
Increase in the prevalence and incidence of endometrial cancer propels the growth of the endometrial cancer diagnostics market globally. As per the stats of American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed and 8010 women died because of it. Furthermore increase in awareness regarding uterine diseases, availability of various treatment options and early diagnostic options drives the growth of the globally. Moreover increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer diagnostics globally. However, low accuracy rate in the results of diagnostic tests, high cost associated with the tests and treatments, adverse effects and lack of awareness about innovative technologies may hinder the growth of the globally.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 22.4 billion |
Market Size in 2030 |
US$ 29.4 billion |
Market CAGR |
5.4% |
By Condition |
|
By Test |
|
By End user |
|
Download Free Sample Report
The global endometrial cancer diagnostics market size was valued at US$ 22.4 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030
Abbott Laboratories, Ariad Pharmaceuticals, Merck, Becton, Dickinson, Siemens Healthcare
Asia Pacific is the fastest-growing region for endometrial cancer diagnostics market
1.Executive Summary |
2.Global Endometrial Cancer Diagnostics Market Introduction |
2.1.Global Endometrial Cancer Diagnostics Market - Taxonomy |
2.2.Global Endometrial Cancer Diagnostics Market - Definitions |
2.2.1.Type |
2.2.2.Test |
2.2.3.End-user |
2.2.4.Region |
3.Global Endometrial Cancer Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Endometrial Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Endometrial Cancer Diagnostics Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Endometrioid Carcinoma |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Serous Adenocarcinoma |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Adenosquamous Carcinoma |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Carcinomasarcoma |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Endometrial Cancer Diagnostics Market By Test, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Hysteroscopy |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Endometrial Biopsy |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Dilation and Curettage |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Ultrasound |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. CT Scan |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. MRI |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Endometrial Cancer Diagnostics Market By End-user, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Diagnostic Centers |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Hospitals |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Ambulatory Surgical Centers |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Endometrial Cancer Diagnostics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Endometrial Cancer Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Endometrioid Carcinoma |
9.1.2.Serous Adenocarcinoma |
9.1.3.Adenosquamous Carcinoma |
9.1.4.Carcinomasarcoma |
9.2. Test Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hysteroscopy |
9.2.2.Endometrial Biopsy |
9.2.3.Dilation and Curettage |
9.2.4.Ultrasound |
9.2.5.CT Scan |
9.2.6. MRI |
9.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Diagnostic Centers |
9.3.2.Hospitals |
9.3.3.Ambulatory Surgical Centers |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Endometrial Cancer Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Endometrioid Carcinoma |
10.1.2.Serous Adenocarcinoma |
10.1.3.Adenosquamous Carcinoma |
10.1.4.Carcinomasarcoma |
10.2. Test Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hysteroscopy |
10.2.2.Endometrial Biopsy |
10.2.3.Dilation and Curettage |
10.2.4.Ultrasound |
10.2.5.CT Scan |
10.2.6. MRI |
10.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Diagnostic Centers |
10.3.2.Hospitals |
10.3.3.Ambulatory Surgical Centers |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11.Asia Pacific (APAC) Endometrial Cancer Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Endometrioid Carcinoma |
11.1.2.Serous Adenocarcinoma |
11.1.3.Adenosquamous Carcinoma |
11.1.4.Carcinomasarcoma |
11.2. Test Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hysteroscopy |
11.2.2.Endometrial Biopsy |
11.2.3.Dilation and Curettage |
11.2.4.Ultrasound |
11.2.5.CT Scan |
11.2.6. MRI |
11.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Diagnostic Centers |
11.3.2.Hospitals |
11.3.3.Ambulatory Surgical Centers |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Endometrial Cancer Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Endometrioid Carcinoma |
12.1.2.Serous Adenocarcinoma |
12.1.3.Adenosquamous Carcinoma |
12.1.4.Carcinomasarcoma |
12.2. Test Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hysteroscopy |
12.2.2.Endometrial Biopsy |
12.2.3.Dilation and Curettage |
12.2.4.Ultrasound |
12.2.5.CT Scan |
12.2.6. MRI |
12.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Diagnostic Centers |
12.3.2.Hospitals |
12.3.3.Ambulatory Surgical Centers |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Endometrial Cancer Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Endometrioid Carcinoma |
13.1.2.Serous Adenocarcinoma |
13.1.3.Adenosquamous Carcinoma |
13.1.4.Carcinomasarcoma |
13.2. Test Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Hysteroscopy |
13.2.2.Endometrial Biopsy |
13.2.3.Dilation and Curettage |
13.2.4.Ultrasound |
13.2.5.CT Scan |
13.2.6. MRI |
13.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Diagnostic Centers |
13.3.2.Hospitals |
13.3.3.Ambulatory Surgical Centers |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Abbott Laboratories (U.S) |
14.2.2.Ariad Pharmaceuticals, Inc. (U.S) |
14.2.3.Merck & Co., Inc. (U.S) |
14.2.4.Becton, Dickinson & Co. (U.S) |
14.2.5.Siemens Healthcare Inc. (Germany) |
14.2.6.Hoffman-La Roche Ltd. (Switzerland) |
14.2.7.GlaxoSmithKline Plc., etc. (UK) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players